PTC Therapeutics, Inc. Announces CHMP Recommends Evrysdi For Babies Under Two Months Old With Spinal Muscular Atrophy
Portfolio Pulse from Happy Mohamed
PTC Therapeutics, Inc. (NASDAQ:PTCT) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the extension of the Evrysdi marketing authorization to include infants under two months of age in the EU. A final decision is expected from the European Commission later this year. Evrysdi is marketed by Roche and in the United States by Genentech, a member of the Roche Group.
July 21, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PTC Therapeutics' Evrysdi has received a positive recommendation from CHMP for use in infants under two months in the EU. This could potentially expand the market for the drug, pending final approval from the European Commission.
The positive recommendation from CHMP for Evrysdi's use in infants under two months old in the EU could potentially expand the market for the drug, pending final approval from the European Commission. This could have a positive impact on PTC Therapeutics' revenues and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100